Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech - LARVOL DELTA

Association between sars-cov-2 infection, COVID-19 vaccines and immune thrombocytopenia in adults. a nationwide population-based study in France. (ASH 2025) - P=N/A | "Although such cases were expected to be sporadic, the possibility of an increased risk at thepopulation level remained uncertain to date.Therefore, we aimed to measure the association between COVID-19 vaccines overall and by type (mRNAvaccines: Comirnaty Pfizer - BNT162b2; Spikevax Moderna - mRNA-12773; and adenovirus-basedvaccines: Vaxzevria AstraZeneca -ChadOx-1-S, and JCovden Janssen AD26COV-2.S) and the occurrence ofITP at the nationwide scale in France. This nationwide population-based study using three different designs showed an associationbetween SARS-CoV-2 infection and ChadOx1-S vaccine with ITP occurrence, while no association wasfound for mRNA vaccines."

Clinical • Hematological Disorders • Immune Thrombocytopenic Purpura • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura

Assessing the association between COVID-19 vaccination and thrombotic thrombocytopenia syndrome (ATTEST Study): Analyses of English data, 2020-2022. (PubMed, Int J Infect Dis) - "Consistent with previous studies, we found an association between TTS and receiving a first dose of AZD1222. There were no associations of TTS with AZD1222 second dose and BNT162b2 first or second doses."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Thrombocytopenia • Thrombosis

Pityriasis rubra pilaris triggered by vaccination. (PubMed, Ital J Dermatol Venerol) - "In conclusion, PRP post-vaccination is rare and likely underdiagnosed, but recognizing the association is important to evaluate any new exposures to the trigger. A thorough patient history, including recent vaccinations, is crucial."

Journal • Dermatology • Infectious Disease • Measles • Mumps • Novel Coronavirus Disease • Pediatrics • Pertussis • Respiratory Diseases • Rubella • Tetanus

Real-world effectiveness of Ad26.COV2.S or BNT162b2 booster vaccines against severe COVID-19 in adults who received a primary dose of Ad26.COV2.S in South Africa during the Delta period: A retrospective cohort study using medical scheme data. (PubMed, S Afr Med J) - "While most participants remained unboosted, administration of either ancestral strain Ad26.COV2.S or BNT162b2 vaccination provided protection against severe COVID-19 outcomes among essential workers in SA during the dominance of the Omicron BA.1 and BA.4/5 variants, demonstrating cross-strain protection."

Journal • Real-world evidence • Retrospective data • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Clot twist - D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS. (PubMed, S Afr Med J) - "Elevated D-dimer levels in asymptomatic, low-risk adults were unexpectedly common and not associated with thromboembolism. This supports the rationale of including D-dimer testing in conjunction with other coagulopathy markers, only if clinically indicated in both COVID-19 vaccine clinical trials and the general population."

Clinical • Journal • P2 data • Cardiovascular • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Obesity • Thrombocytopenia

Adult Onset of Type 2 Familial Hemophagocytic Lymphohistiocytosis After SARS-CoV-2 Vaccination with an Unusual Neurological Onset: The Great Mimic. (PubMed, Diagnostics (Basel)) - "Background and Clinical Significance: This case report describes a 46-year-old male with no prior comorbidities who developed progressive neurological symptoms-ataxia and diplopia-shortly after the second Comirnaty (Pfizer-BioNTech) COVID-19 vaccine dose...The patient had only transient improvement with corticosteroids and then multiple relapses with expanding CNS lesions despite cyclophosphamide, plasmapheresis, and rituximab...This is the first reported case of adult-onset familial HLH presenting predominantly with neurological symptoms following COVID-19 vaccination. The case emphasizes the need to consider genetic forms of HLH in relapsing neuroinflammatory disorders and raises the hypothesis that vaccination may unmask subclinical immune dysregulation in genetically susceptible individuals."

Journal • Ataxia • Bone Marrow Transplantation • CNS Disorders • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Inflammation • Movement Disorders • Multiple Sclerosis • Novel Coronavirus Disease • Rare Diseases • Respiratory Diseases • Transplantation • PRF1

Immunogenicity and safety to SARS-Cov-2 vaccination in patients with systemic vasculitis. (PubMed, Front Immunol) - "ChAdOx1 nCoV-19 (AstraZeneca/Oxford) (n=36) and CoronaVac (Sinovac) (n=25) were primarily the most common vaccines, while BNT162b2 (Pfizer-BioNTech) was usually the booster vaccine...Different SARS-CoV-2 vaccines demonstrated immunogenicity and clinical effectiveness in systemic vasculitis. The three-dose schedule was safe without increasing relapse risk."

Journal • ANCA Vasculitis • Infectious Disease • Novel Coronavirus Disease • Rare Diseases • Respiratory Diseases • Rheumatology • Vasculitis

Inhibition of CXCL10 and IFN-γ ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination. (PubMed, Sci Transl Med) - "Through analysis of human plasma data and in vitro experiments with human macrophages and T cells, we identified increased C-X-C motif chemokine ligand 10 (CXCL10) and interferon-γ (IFN-γ) after exposure to BNT162b2 (Pfizer) or mRNA-1273 (Moderna). In mice exposed to these cytokines or receiving BNT162b2 vaccination, genistein treatment reduced cardiac injury markers and attenuated infiltration of neutrophils and macrophages into the heart. These findings implicate CXCL10-IFN-γ signaling as a contributor to myocardial injury in experimental models of mRNA vaccination and indicate that pharmacologic modulation, such as with genistein, may mitigate cytokine-driven injury."

Journal • Preclinical • Cardiovascular • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • CXCL10 • IFNG

T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children. (PubMed, Open Forum Infect Dis) - P2/3 | "Phase 1 and Phase 2/3 trials (NCT04816643) demonstrated that the mRNA-based coronavirus disease 2019 (COVID-19) vaccine BNT162b2 is tolerable and efficacious in (5-11-year-olds) following two 10 µg doses 21 days apart, and a third 10 µg dose after 6 months. Here, we show that vaccination induces neutralizing antibodies and T-cell immunogenicity in 10-11-year-old participants."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines. (PubMed, Nat Commun) - "Mapping of neutralizing responses indicate greater antigenic overlap of JN.1 and KP.2 vaccines with JN.1 sublineages, while CD4+ and CD8+ T cell responses are conserved across all three vaccines. These data support the selection of JN.1- or KP.2-adapted vaccines for the 2024-25 COVID-19 vaccine formula."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Short- and Long-term Humoral Response of Immunosuppressed Children to SARS-CoV-2 BNT162b2 Vaccine. (PubMed, Pediatr Infect Dis J) - "After 3 vaccine doses, immunosuppressed children demonstrate 6-month immune comparable to healthy children who received 2 doses. Despite a decline in humoral responses over time, there were no infections, supporting the effectiveness of current coronavirus disease 2019 vaccination strategies."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Learning from the omicron BA.4/5 dominance: Strategies for future vaccination preparedness. (PubMed, Vaccine) - "This study provides evidence-based principles for future pandemic vaccination strategies. Platform-switching heterologous boosting (from inactivated vaccines to mRNA vaccines) offers meaningful advantages for inactivated vaccine recipients, bivalent vaccines provide substantial additional protection, and vaccination-first approaches consistently outperform infection-first scenarios. These findings support proactive vaccination policies over reliance on infection-acquired immunity and inform rapid response strategies for future pandemic threats."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Vaccination of Immunodeficient Persons (COVAXID) (clinicaltrials.gov) - P4 | N=539 | Completed | Sponsor: Karolinska University Hospital | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 (clinicaltrials.gov) - P3 | N=330 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naïve and convalescent populations. (PubMed, Vaccine) - "mRNA vaccination provides markedly superior and sustained antibody responses compared to adenoviral vector vaccine, which is particularly relevant for long-term protection strategies."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Reactogenicity and Immunogenicity following Heterologous and Homologous Third Dose COVID-19 vaccination in UK Adolescents (Com-COV3): A Randomised Controlled Non-Inferiority Trial. (PubMed, J Infect) - "All booster regimens evaluated elicited a robust immune response. 10μg fractional adult BNT162b2 vaccine demonstrated similar immunogenicity compared with 30μg BNT162b2 and superior immunogenicity compared with 10μg paediatric BNT162b2 vaccine. Fractional doses of the adult BNT162b2 vaccine are an alternative to the paediatric formulation for booster campaigns in adolescents."

Head-to-Head • Journal • Infectious Disease • Meningococcal Infections • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases

Longitudinal proteomic and autoantibody signatures after mRNA vaccination in healthy individuals. (PubMed, Vaccine) - "Integrated plasma proteomics and autoantibody profiling demonstrated sustained immunogenicity and safety of SARS-CoV-2 mRNA vaccines, characterized by durable spike-specific antibody responses, late-onset complement activation, and limited autoantibody induction. These findings enhance our understanding of vaccine-induced immunity and inform long-term monitoring and optimization of mRNA vaccine strategies."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Thrombosis • IL1B

Cytokine and Antibody Isotype Responses in Vaccinated Healthcare Workers with SARS-CoV-2 Breakthrough Infections. (PubMed, Viruses) - "Our data show that breakthrough infections in vaccinated HCWs induce a robust pro-and anti-inflammatory cytokine profile, which is associated with a broader IgM response directed against both NCP and RBD."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CXCL8 • IFNG • IL10 • IL2 • IL6 • TGFB1 • TNFA

Estimating the Optimal COVID-19 Booster Timing Using Surrogate Correlates of Protection: A Longitudinal Antibody Study in Naïve and Previously Infected Individuals. (PubMed, Pathogens) - "In a prospective cohort of 177 Japanese healthcare workers, we longitudinally monitored anti-spike receptor-binding domain (S-RBD) antibody titers following BNT162b2 vaccination...These substantial differences underscore the limitations of uniform booster schedules. Our findings provide a quantitative framework for personalized vaccination strategies based on individual antibody profiles and immune status, thereby optimizing protection."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Incidence of stroke following COVID-19 vaccination: a nationwide self‑controlled risk interval study in Qatar. (PubMed, Expert Rev Vaccines) - "IRRs for the 0-21-day window were 1.39 (95% CI: 1.08-1.80) for BNT162b2 and 1.15 (95% CI: 0.78-1.69) for mRNA-1273. By subtype, IRRs were 1.34 (95% CI: 1.07-1.68) for ischemic stroke, 1.11 (95% CI: 0.58-2.11) for hemorrhagic stroke, and 1.46 (95% CI: 0.38-5.56) for cerebral venous sinus thrombosis. A small, transient increase in stroke incidence was observed within 21 days of vaccination; however, such events remain exceedingly rare, with an estimated excess risk substantially lower than that typically associated with infection."

Journal • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Infectious Disease • Ischemic stroke • Novel Coronavirus Disease • Thrombosis

Observations of Wart Clearance Following COVID-19 Vaccination: Coincidence or Missed Immunologic Signals? (PubMed, Vaccines (Basel)) - "Clearance occurred within approximately 2-4 weeks following the second or third vaccine dose (either mRNA-based [BNT162b2, mRNA-1273] or adenoviral vector [ChAdOx1-S]) and was sustained for 2-8 months of follow-up with no recurrences reported. While causality cannot be determined, the convergence of reports across diverse patients, consistent timing of clearance, and plausible immunologic pathways suggest that COVID-19 vaccination may, in rare instances, trigger beneficial immune activation against HPV-infected keratinocytes. Recognition of such unexpected outcomes underscores the need for broader vaccine safety and efficacy surveillance that includes both adverse and beneficial immune effects."

Journal • Dermatology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Primary and Booster COVID-19 Vaccination in Patients with Sjögren's Disease: Data from the Longitudinal SAFER Cohort Study. (PubMed, Vaccines (Basel)) - "COVID-19 vaccination in patients with SjD was safe and induced high anti-spike antibody titers and seropositivity. Heterologous boosting, particularly with BNT162b2, demonstrated superior immunogenicity. No association was found between vaccination and SjD disease flares or worsening activity."

Journal • Immunology • Infectious Disease • Novel Coronavirus Disease • Sjogren's Syndrome

Immunogenicity and Safety of Half and Full Doses of Heterologous and Homologous COVID-19 Vaccine Boosters After Priming with ChAdOx1 in Adult Participants in Indonesia: A Single-Blinded Randomized Controlled Trial. (PubMed, Vaccines (Basel)) - "One serious adverse event was reported, assessed as unrelated to the vaccine. This study confirms that half doses of ChAdOx1-S and BNT162b2 are as immunogenic and safe as full doses, and a heterologous booster is more immunogenic than a homologous booster."

Journal • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Pain • Respiratory Diseases

Two-Year Follow-Up of Humoral and Cellular Immune Responses to SARS-CoV-2 in Healthcare Professionals. (PubMed, Vaccines (Basel)) - "The study demonstrates long-term durability of IgG and neutralizing antibodies and confirms durable cellular immunity up to two years postvaccination. Hybrid immunity significantly enhanced neutralizing antibody levels, supporting its added value in protective immunity against SARS-CoV-2."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Longitudinal Study of IgG Antibody Levels Over 4.5 Years Until the Fifth Booster mRNA Vaccination and Breakthrough Infection: A Case Report. (PubMed, Cureus) - "This case study examined a 71-year-old Japanese man who received his seventh dose (fifth booster) of the mRNA BNT162b2 vaccine and subsequently experienced his first breakthrough infection 80 days after vaccination...The decline in antibody titers after breakthrough infection was modeled using the equation f(t) = Aexp(-t/τ) + C. These findings suggest that humoral immune responses are maintained at elevated levels for an extended period. This case provides valuable insights into vaccination strategies for breakthrough infections."

Journal • Observational data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases